• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Progressive multifocal leukoencephalopathy masquerading as cerebellar infarction
We report the case of a patient who present a stroke unit with symptoms that were consistent initially with a posterior circulation stroke. Prior chemotherapy with Rituximab, for a lymphoma, had predisposed the patient to infection with the JC virus. Physicians need to be aware of the condition, and patients need to aware of these risks of chemotherapy.
Source: Age and Ageing - June 21, 2016 Category: Geriatrics Authors: Willott, R. H., Sunman, W., Munshi, S. K. Tags: Case Reports Source Type: research

The use of a Berlin Heart EXCOR LVAD in a child receiving chemotherapy for Castleman's disease
We present the unique case of a pediatric patient who received chemotherapy for a diagnosis of CD, while mechanically supported with a Berlin EXCOR LVAD secondary to restrictive cardiomyopathy. A four‐yr‐old previously healthy male with restrictive cardiomyopathy required MCS after cardiac arrest but was diagnosed with multicentric CD, a non‐malignant lymphoproliferative disorder fueled by excessive IL‐6 production. Treatment with IL‐6 blockade (tocilizumab) every two wk and methylprednisolone had no effect on his lymph nodes or cardiac function while on temporary RotaFlow. A Berlin LVAD was placed for treatment...
Source: Pediatric Transplantation - December 1, 2014 Category: Transplant Surgery Authors: Tamara O. Thomas, Shanmuganathan Chandrakasan, Maureen O'Brien, John L. Jefferies, Thomas D. Ryan, Ivan Wilmot, Michael L. Baker, Peace C. Madueme, David Morales, Angela Lorts Tags: Case Report Source Type: research

Clinical Spectrum and Course in Individuals with Intravascular Large B-Cell Lymphoma Affecting the Nervous System: A Case Series (P01.102)
CONCLUSIONS: Although IVLBL has distinct pathological features, its clinical presentation can be protean, ranging from mild myopathy to fulminant brain or multi-organ failure. The patient's optimal chance for survival relies on early pathological diagnosis and prompt, aggressive chemotherapy.Disclosure: Dr. Zhong has nothing to disclose. Dr. Oakes has nothing to disclose. Dr. Sonnen has nothing to disclose. Dr. Ransom has nothing to disclose. Dr. Longstreth has nothing to disclose. Dr. Mrugala has received personal compensation for activities with UCB Pharma, Sigma-Tau Pharmaceuticals, and Perceptive Informatics. Dr. Mruga...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Zhong, N., Oakes, P., Sonnen, J., Ransom, B., Longstreth, W. T., Mrugala, M. Tags: P01 Neuro-Oncology: Therapeutics Source Type: research